Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Milrinone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the terms of the agreement, Hyloris will be responsible for the development, manufacturing, regulatory affairs, and commercialisation of CRD-102. CRD-102 is a novel, patented, extended-release Milrinone capsule.
Brand Name : CRD-102
Molecule Type : Small molecule
Upfront Cash : $0.1 million
October 08, 2021
Lead Product(s) : Milrinone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Milrinone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Caplin Steriles Gets US FDA Approval for Generic Bloxiverz Injection
Details : Caplin Steriles has been granted final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) neostigmine methylsulfate injection USP, 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2021
Lead Product(s) : Milrinone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Milrinone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Caplin Steriles Receives Final USFDA Approval for Milrinone Lactate Injection
Details : Caplin Steriles has been granted final approval from the USFDA for its ANDA Milrinone Lactate Injection USP, 10 mg/10 mL, 20 mg/20 mL, 50 mg/50 mL, Single-dose vial presentation, a generic therapeutic equivalent version of, PRIMACOR Injection, 1 mg/mL, o...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2021
Lead Product(s) : Milrinone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?